Premium
Exploring the Potential of Metallodrugs as Chemotherapeutics for Triple Negative Breast Cancer
Author(s) -
Nayeem Nazia,
Contel Maria
Publication year - 2021
Publication title -
chemistry – a european journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.687
H-Index - 242
eISSN - 1521-3765
pISSN - 0947-6539
DOI - 10.1002/chem.202100438
Subject(s) - triple negative breast cancer , breast cancer , cancer research , in vivo , cancer , medicine , oncology , chemistry , biology , microbiology and biotechnology
This review focuses on studies of coordination and organometallic compounds as potential chemotherapeutics against triple negative breast cancer (TNBC) which has one of the poorest prognoses and worst survival rates from all breast cancer types. At present, chemotherapy is still the standard of care for TNBC since only one type of targeted therapy has been recently developed. References for metal‐based compounds studied in TNBC cell lines will be listed, and those of metal‐specific reviews, but a detailed overview will also be provided on compounds studied in vivo (mostly in mice models) and those compounds for which some preliminary mechanistic data was obtained (in TNBC cell lines and tumors) and/or for which bioactive ligands have been used. The main goal of this review is to highlight the most promising metal‐based compounds with potential as chemotherapeutic agents in TNBC.